Pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in renal and hepatic impairment patients

Clinical Pharmacology in Drug Development

Volumn 3, Issue 1, 2014, Pages 34-42

  Chen, Xuejun ^a   Shi, Jack G ^a   Emm, Thomas ^a   Scherle, Peggy A ^a   Mcgee, Ryan F ^a   Lo, Yvonne ^a   Landman, Robert R ^a   Punwani, Naresh G ^a   Williams, William V ^a   Yeleswaram, Swamy ^a  

^a Drug Metabolism Pharmacokinetics Clinical Pharmacology   (United States)

Author keywords

Hepatic impairment; Pharmacodynamics; Pharmacokinetics; Renal impairment; Ruxolitinib

Indexed keywords

RUXOLITINIB;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; COLD SWEAT; CONTROLLED STUDY; DISEASE ASSOCIATION; DIZZINESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; INTRAOCULAR PRESSURE ABNORMALITY; KIDNEY DYSFUNCTION; LIMIT OF QUANTITATION; LIVER DYSFUNCTION; MALE; MAXIMUM PLASMA CONCENTRATION; MILD RENAL IMPAIRMENT; MODERATE RENAL IMPAIRMENT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SEVERE RENAL IMPAIRMENT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; YOUNG ADULT;

EID: 84892474725     PISSN: 2160763X     EISSN: 21607648     Source Type: Journal    
DOI: 10.1002/cpdd.77     Document Type: Article

References (24)

1. Quintás-Cardama A, Vaddi K, Liu P, et al. Preclinical characterization of the selective JAK1/2 inhibitor RUXOLITINIB: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood. 2010; 115:3109-3117.
2. Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010; 363:1117-1127.
3. Verstovsek S, Passamonti F, Rambaldi A, et al. Durable Responses with the JAK1/JAK2 Inhibitor, INCB018424, in Patients with Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Refractory or Intolerant to Hydroxyurea (HU). Presentation on the American Society of Hematology (ASH) Annual Conference, 2010. http://investor.incyte.com/phoenix.zhtml?c=69764&p=irol-presentations.
4. Shi JG, Chen X, McGee RF, et al. The pharmacokinetics, pharmacodynamics, and safety of orally dosed INCB018424 phosphate in healthy volunteers. J Clin Pharmacol. 2011; 51:1644-1654.
5. 14C] INCB018424, a selective Janus tyrosine kinase 1/2 inhibitor, in humans. Drug Metab Dispos. 2010; 38:2023-2031.
6. Shi JG, Chen X, Emm T, et al. The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers. J Clin Pharmacol. 2012; 52:809-818.
7. Child CG, Turcotte JG. Surgery and portal hypertension. In: Child CG, ed. The Liver and Portal Hypertension, Philadelphia: Saunders; 1964: 50-64.
8. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973; 60:648-652.
9. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999; 130:461-470.
10. Robbins-Weilert D. Design, conduct and analysis of studies in patients with renal impairment, pharmacokinetics in drug development: clinical study design and analysis. AAPS 2004; 1:177-208.
11. Yin OQ, Gallagher N, Tanaka C, et al. Effects of hepatic impairment on the pharmacokinetics of nilotinib: an open-label, single-dose, parallel-group study. Clin Ther. 2009; 31(Pt2):2459-2469.
12. Moton A, Krishna G, Ma L, et al. Pharmacokinetics of a single dose of the antifungal posaconazole as oral suspension in subjects with hepatic impairment. Curr Med Res Opin. 2010; 26:1-7.
13. Areberg J, Christophersen JS, Poulsen MN, Larsen F, Molz KH. The pharmacokinetics of escitalopram in patients with hepatic impairment. AAPS J. 2006; 8(1):E14-E19.
14. Vaidyanathan S, Warren V, Yeh C, Bizot MN, Dieterich HA, Dole WP. Pharmacokinetics, safety, and tolerability of the oral Renin inhibitor aliskiren in patients with hepatic impairment. J Clin Pharmacol. 2007; 47(2):192-200.
15. Dreisbach AW, Lertora JJ. The effect of chronic renal failure on hepatic drug metabolism and drug disposition. Semin Dial. 2003; 16(1):45-50.
16. Pichette V, Leblond FA. Drug metabolism in chronic renal failure. Curr Drug Metab. 2003; 4(2):91-103.
17. Sun H, Frassetto L, Benet LZ. Effects of renal failure on drug transport and metabolism. Pharmacol Ther. 2006; 109(1-2):1-11.
18. Nolin TD, Naud J, Leblond FA, Pichette V. Emerging evidence of the impact of kidney disease on drug metabolism and transport. Clin Pharmacol Ther. 2008; 83(6):898-903.
19. Zhang Y, Zhang L, Abraham S, et al. Assessment of the impact of renal impairment on systemic exposure of new molecular entities: evaluation of recent new drug applications. Clin Pharmacol Ther. 2009; 85(3):305-311.
20. US Food Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry Pharmacokinetics in Patients With Impaired Renal Function: Study Design, Data Analysis, and Impact on Dosing and Labeling, Drafted Guidance, March 2010; Revision 1. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM204959.pdf (Accessed October 25, 2012).
21. Huang SM, Temple R, Xiao S, Zhang L, Lesko LJ. When to conduct a renal impairment study during drug development: US Food and Drug Administration perspective. Clin Pharmacol Ther. 2009; 86(5):475-479.
22. Touchette MA, Slaughter RL. The effect of renal failure on hepatic drug clearance. DICP. 1991; 25(11):1214-1224.
23. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012; 366:799-807.
24. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012; 366:787-798.